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Dear Editor,
Ochrobactrum pseudogrignonense is a gram-negative, non-
spore-forming, aerobic bacillus, rarely encountered in clinical 
specimens. It was originally isolated in Scandinavia from the 
blood of a 28-year-old man in 1992 and the ear of a newborn in 
2000 [1]. Since then, O. pseudogrignonense has been isolated 
from environmental sources [2-4]; however, its pathogenicity in 
humans has not been explored extensively. We report the first 
case of O. pseudogrignonense bacteremia in Korea—and only 
the third in the world [1], to our knowledge—and species identi-
fication was verified by 16S rRNA and recA gene sequencing. 
This study was approved by the Institutional Review Board (IRB) 
of Yonsei University of Medicine, Seoul, Korea (2019-1369). 
This is a retrospective report and hence IRB approval was ob-
tained without consent forms.
A 44-year-old man with hypertension, diabetes mellitus, and 
dilated cardiomyopathy presented with aggravated dyspnea and 
falling blood pressure and was admitted to a hospital in March 
2018. After three days, the patient received extracorporeal mem-
brane oxygenation (ECMO) and was referred to a tertiary-care 
hospital in Seoul for heart transplantation. After transfer, the pa-
tient’s vital signs were as follows: blood pressure, 110/87 mm 
Hg; pulse rate, 120/minutes; respiration rate, 16/minutes; and 
body temperature, 36.5°C. The initial laboratory results were as 
follows: hemoglobin, 175 g/L; white blood cell (WBC) count, 
28.5×109/L; and platelet count, 118×109/L. The patient was 
initially placed on a vancomycin and piperacillin-tazobactam 
regimen. Although the patient had no fever one day after admis-
sion, his serum C-reactive protein level was 514.3 nmol/L, WBC 
count was 42.6×109/L, and delta neutrophil index was 12.4%, 
suggesting an increased immature granulocyte fraction [5]. As 
fever may not be apparent in ECMO patients with bacteremia [6] 
and considering the deteriorated laboratory results, the antibi-
otic regimen was changed from piperacillin-tazobactam to me-
ropenem. 
One set of aerobic and anaerobic blood cultures from the cen-
tral venous line and two sets from different peripheral venipunc-
tures were collected before initiation of antibiotic therapy and 
incubated for 36 hours in the BACT/ALERT 3D blood culture 
system (bioMérieux, Durham, NC, USA). All three aerobic vials 
demonstrated bacterial growth; they formed beige, non-hemo-
lytic, distinct small circular colonies on blood and MacConkey 
agar plates within 24 hours of incubation at 35°C (Fig. 1A & B). 
Gram-staining indicated gram-negative, rod-shaped bacteria 
without spores (Fig. 1C). Matrix-assisted laser desorption/ioniza-
tion time-of-flight mass spectrometry (MALDI-TOF MS; Bruker 
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Daltonics, Bremen, Germany) of the isolate revealed signals char-
acteristic of O. gallinifaecis with a score of 1.81; however, both 
the VITEK MS and VITEK2 systems (bioMérieux, Marcy l’Etoile, 
France) failed to identify the isolate. 
To characterize the bacterium, molecular identification was 
performed by DNA amplification and sequencing of 16S rRNA 
[7]. Based on the EzTaxon database (http://www.ezbiocloud.
net), both 373 and 1,374 bp 16S rRNA sequences of the iso-
late shared 100% sequence identity with those of O. pseudogri-
gnonense (GenBank accession number AM422371) and 99.3% 
with those of Ochrobactrum thiophenivorans (GenBank number 
AM490617). Based on the Ribosomal Database Project (https://
rdp.cme.msu.edu/), the isolate had a sequence match score of 
1.0 for O. pseudogrignonense and 0.96 for O. thiophenivorans. 
As 16S rRNA did not provide the resolution to distinguish the 
species [7], alternative analysis using the recA gene was per-
formed [8, 9]. We constructed primer pairs for partial sequenc-
ing O. pseudogrignonense (GenBank number AM422877.1) 
and O. thiophenivorans (GenBank number KF866345) recA: 
recA-O.pseudo-f (5´-TTCGGGTAAAACCACTCTCG-3´)/recA-O.
pseudo-r (5´-ATGTCGAACTCGACCTGCTT-3´) and recA-O.thio-f 
(5´-GCAAGGGCTCAATCATGC-3´)/recA-O.thio-r (5´-AATCACCC-
ATTTCACCTTCG-3´). The isolate was amplified successfully only 
with the O. pseudogrignonense recA primer pair (510 bp). This 
PCR product shared 100% sequence identity with the recA gene 
of O. pseudogrignonense, as determined using the GenBank 
alignment search tool (BLAST; https://blast.ncbi.nlm.nih.gov/
Blast.cgi). 
We performed antimicrobial susceptibility testing (AST) of the 
isolate using the VITEK2 system with the AST-N225 card, which 
was interpreted based on the breakpoints for other non-Entero-
bacteriaceae [10]. The results showed that the isolate was sus-
ceptible to meropenem and resistant to piperacillin-tazobactam 
(Table 1). Consistent with the AST results, two days after me-
ropenem treatment, the patient’s WBC count decreased to 16.0 
×109/L, and blood culture results were negative for five days. The 
patient recovered without any evident sequelae. 
Table 1. Antimicrobial susceptibilities of the O. pseudogrignonense 
isolate 

















Abbreviations: MIC, minimum inhibitory concentration; S, susceptible; R, 
resistant.
Fig. 1. Colony and microscopic morphology of the O. pseudogrignonense isolate. (A) Colonies on blood agar (10×) and (B) MacConkey 
agar (10×) plates. (C) Gram staining of the isolate (1,000×).
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Ochrobactrum species are emerging pathogens with low viru-
lence that can cause severe systemic infections not only in pa-
tients with underlying diseases but also in immunocompetent 
patients [8, 9]. This is the first case of human infection with O. 
pseudogrignonense in Korea. As the isolate showed resistance 
to piperacillin-tazobactam, accurate identification and AST were 
critical for timely and appropriate treatment; however, it was dif-
ficult to identify the isolate using commercial bacterial identifica-
tion kits and MALDI-TOF MS. Owing to the high similarity of 16S 
rRNA sequences among Ochrobactrum species, as well as Bru-
cella species [8, 9], additional sequencing, such as of the recA 
gene, is needed for accurate species-level identification.
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